[Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
Based on the established electrophoretic mobility of L-DOPA and on pathogenetic assumptions, the authors carried out multiple modality treatment employing transcerebral L-DOPA electrophoresis in 48 patients with postencephalic and atherosclerotic parkinsonism. The majority of patients (43 subjects) showed an improvement of various degrees, particularly when rigidity and oligo- and bradykinesia were predominant in the clinical picture of the disease. Of the 48 patients treated, 29 received L-DOPA per os and 19 patients were given low drug doses. The therapeutic effect persisted from 2 weeks to 2-3 months.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004586:Electrophoresis; D005260:Female; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000150:complications; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000188:drug therapy / Q000209:etiology
D007980:Levodopa
Transtserebral'nyĭ élektroforez L-DOPA v kompleksnom lechenii parkinsonizma.